On December 23, Katrina J. Church, Senior Vice President and Chief Compliance Officer of Bioventus Inc. (NASDAQ:), sold 2,535 shares of the company’s Class A common stock. The shares were traded at a weighted average price of $10.53, amounting to a total transaction value of $26,693. The transaction comes as Bioventus stock has shown remarkable resilience, posting a 102% gain over the past year. According to InvestingPro data, analysts maintain a positive outlook with price targets ranging from $13 to $17.

This sale was made to cover taxes on the transfer of restricted stock units, according to the 10b5-1 instruction adopted in June 2023. After this transaction, the Church retained ownership of 47,264 shares of Bioventus. Want deeper insight into insider transactions and comprehensive analysis? InvestingPro offers exclusive access to detailed insider trading patterns and 8 additional key insights about Bioventus, along with a professional research report that transforms complex data into actionable intelligence.

In other recent news, Bioventus, an orthobiologic solution provider, reported impressive growth in the third quarter, with a 15% increase in revenue year-over-year to $139 million. The company also raised its full-year revenue guidance to between $562 million and $567 million, indicating expected growth of around 13%. The main growth drivers are identified as surgical solutions, especially in ultrasonics and bone graft substitutes, and the HA business for knee osteoarthritis. Additionally, the company’s adjusted EBITDA increased 9% to $24 million, with an expected annual margin improvement of 100 basis points.

Bioventus also announced the sale of its advanced rehabilitation business for $25 million, with potential proceeds of up to $20 million. The company aims to reduce its net leverage to less than 3 times by the end of 2025 and increase its cash position by $43 million. Adjusted earnings per share guidance for the full year was increased to $0.40 to $0.42.

Despite expecting a lower growth rate in Q4 due to challenging year-over-year comparisons and a temporary slowdown in onboarding new distributor agents, Bioventus remains confident of continued growth. -on its performance to 2025. The company is optimistic about growth driven by a strong position in the HA market and a disciplined resource allocation strategy. These developments reflect the company’s strategic initiatives aimed at driving growth and profitability.

This article was created with the support of AI and reviewed by an editor. For more information see our T&C.